<DOC>
	<DOC>NCT00759941</DOC>
	<brief_summary>The purpose of this study was to assess the efficacy of adding Azopt dosed three times a day to Xalatan as compared to that of adding placebo to Xalatan in patients with elevated intraocular pressure.</brief_summary>
	<brief_title>A Comparison of Azopt Versus Placebo Added to Xalatan in Patients With Elevated Intraocular Pressure (IOP) on a Prostaglandin</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Brinzolamide</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Unilateral or bilateral primary open angle glaucoma, ocular hypertension or pseudoexfoliation syndrome. Intraocular pressure greater than 18 mmHg (mean diurnal) and less than 32 mmHg. Other protocoldefined inclusion criteria applied. Exclusion: Previous intraocular surgery, except uncomplicated clear cornea phacoemulsification or argon laser trabeculoplasty. Argon laser trabeculoplasty or phacoemulsification within the last 3 months. Central corneal thickness outside the 500 600 (inclusive) micron range as measured by ultrasonic pachymetry. Ocular or periocular inflammation within 3 months prior to study (except blepharitis related or seasonal allergic conjunctivitis). History of uveitis or previous intraocular inflammation (other than postoperatively). Hypersensitivity to sulfa, or benzalkonium chloride. History of use of any steroids for over 1 week within 3 months of screening or likely need for any corticosteroids during the study (except inhaled, nasal or topical nonocular). Other protocoldefined exclusion criteria applied.</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Glaucoma</keyword>
</DOC>